The Possible Protective Effect of Ranolazine, Ivabradine and Trimetazidine on Experimentally Induced Diabetic Nephropathy in Rats
Zein El-Abdeen Ahmed, S., Mohamed, A., Abdullah, O., Sorour, S., Fawzy, E. (2024). The Possible Protective Effect of Ranolazine, Ivabradine and Trimetazidine on Experimentally Induced Diabetic Nephropathy in Rats. EKB Journal Management System, 41(1), 270-287. doi: 10.21608/bmfj.2024.265367.2003
Salwa Ali Zein El-Abdeen Ahmed; Ahmed Selim Mohamed; Omaima Mohamed Abdullah; Safwa Mahmoud Sorour; Eman Mahmoud Fawzy. "The Possible Protective Effect of Ranolazine, Ivabradine and Trimetazidine on Experimentally Induced Diabetic Nephropathy in Rats". EKB Journal Management System, 41, 1, 2024, 270-287. doi: 10.21608/bmfj.2024.265367.2003
Zein El-Abdeen Ahmed, S., Mohamed, A., Abdullah, O., Sorour, S., Fawzy, E. (2024). 'The Possible Protective Effect of Ranolazine, Ivabradine and Trimetazidine on Experimentally Induced Diabetic Nephropathy in Rats', EKB Journal Management System, 41(1), pp. 270-287. doi: 10.21608/bmfj.2024.265367.2003
Zein El-Abdeen Ahmed, S., Mohamed, A., Abdullah, O., Sorour, S., Fawzy, E. The Possible Protective Effect of Ranolazine, Ivabradine and Trimetazidine on Experimentally Induced Diabetic Nephropathy in Rats. EKB Journal Management System, 2024; 41(1): 270-287. doi: 10.21608/bmfj.2024.265367.2003

The Possible Protective Effect of Ranolazine, Ivabradine and Trimetazidine on Experimentally Induced Diabetic Nephropathy in Rats

Benha Medical Journal
Article 25, Volume 41, Issue 1, March and April 2024, Page 270-287  XML PDF (1.68 MB)
Document Type: Original Article
DOI: 10.21608/bmfj.2024.265367.2003
View on SCiNiTO View on SCiNiTO
Authors
Salwa Ali Zein El-Abdeen Ahmed1; Ahmed Selim Mohamed2; Omaima Mohamed Abdullah3; Safwa Mahmoud Sorour1; Eman Mahmoud Fawzy email 4
1Department of Clinical Pharmacology, Faculty of Medicine, Benha University
2Department of Clinical pharmacology , Benha faculty of medicine, Benha university, Benha, Egypt
3Department of Clinical Pharmacology , Faculty of Medicine, Benha University
4Pharmacology department benha faculty of medicine, ,Qaluobia, Egypt
Abstract
Background: The prevalence of diabetes has been increasing exponentially both in developing and developed nations. Diabetic nephropathy (DN) is the leading cause of end-stage renal disease (ESRD) across the world. Aim of the study: this work aimed to explore the potential efficacy of ranolazine, ivabradine and trimetazidine in prevention of development and progression of experimentally induced diabetic nephropathy in nicotinamide- streptozotocin (NA-STZ) type 2 diabetic rats’ model. Materials and Methods: 30 Rats were divided into: (Group I) normal control group, (Group II) non treated diabetic group received no treatment, (group III) ranolazine treated diabetic group received ranolazine (20 mg/kg twice daily), (Group IV) ivabradine treated diabetic group received ivabradine (10 mg/kg/day), (Group V) trimetazidine treated diabetic group received trimetazidine (10 mg/kg/day). Results: ranolazine, ivabradine and trimetazidine induces significant decrease in fasting blood glucose, renal function parameters, renal MDA and renal iNOS in renal homogenate. Serum inflammatory marker (RBP) also significantly decreased together with genes of vascular damage (ET-1), significant down regulation of m RNA in Caspase-3 level and TGFB-1 was downregulated compared with diabetic non treated rats. Conclusion: Current findings confirmed ameliorative impact of ivabradine, trimetazidine and ranolazine on DN induced by NA-STZ T2DM. Ivabradine showed the best effect followed by trimetazidine. Ranolazine treated group had the lowest prophylactic effect.
Keywords
Diabetic Nephropathy; Ranolazine; Ivabradine; Trimetazidine; Gene Expression
Statistics
Article View: 89
PDF Download: 117